Vinpocetine Effect on the Juncture of Diabetes and Aging: An In-Vitro Study Publisher Pubmed



Moininodeh S¹ ; Rahimifard M¹ ; Baeeri M¹ ; Hodjat M^{1, 2} ; Haghiaminjan H^{3, 4} ; Abdollahi M¹ Show Affiliations
Source: Drug Research Published:2021

Abstract

Background The rapid-growing population of diabetic patients and the elderly are among the direst challenges that the science of medicine is facing today. Targeting these two challenges can shed light on new means to control and ideally reverse this trend. In this experiment, Vinpocetine's effect on aged pancreatic beta-cell functions in correlation with oxidative stress was studied. Methods Islet cells were isolated from the pancreas of aged rats and exposed to Vinpocetine, dissolved in acetone and RPMI, for 48 h. Then, senescence-associated molecular parameters, including P16 and P38 gene expressions and β-galactosidase activity, were investigated along with diabetic and inflammation markers. Results Experimental results showed that Vinpocetine could significantly increase aged islets insulin secretion and also make a meaningful reduction in oxidative stress markers. This drug can also decrease expression levels of P16 and P38, the primary genes responsible for the aging pathway. TNF-α, IL-6, and NF-κB expressions were also reduced noticeably after treatment with Vinpocetine. Conclusion The current study showed that Vinpocetine, a derivative of the secondary plant metabolite called Vincamine, could break this vicious cycle of oxidative stress and aging by reducing oxidative stress and inflammation, thus inhibiting cellular aging. © 2021. Thieme. All rights reserved.